TWI858258B - Lnp023之結晶形式 - Google Patents

Lnp023之結晶形式 Download PDF

Info

Publication number
TWI858258B
TWI858258B TW110117696A TW110117696A TWI858258B TW I858258 B TWI858258 B TW I858258B TW 110117696 A TW110117696 A TW 110117696A TW 110117696 A TW110117696 A TW 110117696A TW I858258 B TWI858258 B TW I858258B
Authority
TW
Taiwan
Prior art keywords
lnp023
composition
crystalline hydrate
hydrate form
hydrochloride
Prior art date
Application number
TW110117696A
Other languages
English (en)
Chinese (zh)
Other versions
TW202204335A (zh
Inventor
子辰 賈
菲力浦 路司丹伯格
馬西莫 摩拉托
瑪麗 梅耶爾
Original Assignee
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商諾華公司 filed Critical 瑞士商諾華公司
Publication of TW202204335A publication Critical patent/TW202204335A/zh
Application granted granted Critical
Publication of TWI858258B publication Critical patent/TWI858258B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW110117696A 2020-05-18 2021-05-17 Lnp023之結晶形式 TWI858258B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063026637P 2020-05-18 2020-05-18
US63/026,637 2020-05-18
US202063052699P 2020-07-16 2020-07-16
US63/052,699 2020-07-16

Publications (2)

Publication Number Publication Date
TW202204335A TW202204335A (zh) 2022-02-01
TWI858258B true TWI858258B (zh) 2024-10-11

Family

ID=76076387

Family Applications (2)

Application Number Title Priority Date Filing Date
TW110117696A TWI858258B (zh) 2020-05-18 2021-05-17 Lnp023之結晶形式
TW113137576A TW202504893A (zh) 2020-05-18 2021-05-17 Lnp023之結晶形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW113137576A TW202504893A (zh) 2020-05-18 2021-05-17 Lnp023之結晶形式

Country Status (10)

Country Link
US (3) US11603363B2 (cg-RX-API-DMAC7.html)
EP (1) EP4153580A1 (cg-RX-API-DMAC7.html)
JP (3) JP7592743B2 (cg-RX-API-DMAC7.html)
KR (2) KR20230009478A (cg-RX-API-DMAC7.html)
CN (4) CN120168469A (cg-RX-API-DMAC7.html)
AU (2) AU2021276912B2 (cg-RX-API-DMAC7.html)
CA (1) CA3180829A1 (cg-RX-API-DMAC7.html)
IL (1) IL297975A (cg-RX-API-DMAC7.html)
TW (2) TWI858258B (cg-RX-API-DMAC7.html)
WO (1) WO2021234544A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251596T1 (hr) 2017-08-31 2026-01-30 Novartis Ag Nove upotrebe derivata piperidinil-indola
CN120168469A (zh) * 2020-05-18 2025-06-20 诺华股份有限公司 Lnp023的结晶形式
US11951101B2 (en) 2020-07-16 2024-04-09 Novartis Ag Methods of using factor B inhibitors
US20240109861A1 (en) * 2020-12-30 2024-04-04 Medshine Discovery Inc. Series of piperidine-substituted benzoic acid compounds, and use thereof
WO2022234541A1 (en) * 2021-05-07 2022-11-10 Novartis Ag Iptacopan for the treatment of atypical hemolytic uremic syndrome
US20240277689A1 (en) 2021-06-18 2024-08-22 Novartis Ag Method of treating an autoimmune hematological disorder
WO2023166487A1 (en) 2022-03-04 2023-09-07 Novartis Ag Use of iptacopan for the treatment of lupus nephritis
KR20250027806A (ko) * 2022-06-30 2025-02-27 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 질소 함유 브릿지 헤테로시클릭 유도체의 약학적으로 허용 가능한 염, 결정형 및 이의 제조 방법
AU2024226444A1 (en) 2023-02-23 2025-07-24 Novartis Ag Methods of using factor b inhibitors
TW202508580A (zh) 2023-08-25 2025-03-01 瑞士商諾華公司 使用因子b抑制劑之方法
AU2024417894A1 (en) * 2024-01-10 2026-07-30 Hebei Yiling Medicine Research Institute Co. Ltd. Piperidinyl indole derivative, preparation method therefor and use thereof
WO2025172910A1 (en) 2024-02-16 2025-08-21 Novartis Ag Factor b inhibitors for treatment of anca-associated vasculitis
WO2026003809A1 (en) 2024-06-29 2026-01-02 Assia Chemical Industries Ltd. Solid state forms of iptacopan hydrochloride
WO2026093943A1 (en) 2024-10-31 2026-05-07 Novartis Ag Chemical process for preparing phenylpiperidinyl indole derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
WO2011153221A1 (en) 2010-06-01 2011-12-08 Plus Chemicals Sa Solid state forms of ixabepilone
JO3425B1 (ar) * 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
LT3394089T (lt) 2015-12-23 2021-11-25 eleva GmbH Polipeptidai, skirti komplemento aktyvacijos inhibicijai
HRP20251596T1 (hr) 2017-08-31 2026-01-30 Novartis Ag Nove upotrebe derivata piperidinil-indola
CN120168469A (zh) * 2020-05-18 2025-06-20 诺华股份有限公司 Lnp023的结晶形式

Also Published As

Publication number Publication date
TW202204335A (zh) 2022-02-01
JP2026048795A (ja) 2026-03-17
CN120172955A (zh) 2025-06-20
JP2023518552A (ja) 2023-05-02
JP2024150466A (ja) 2024-10-23
AU2021276912B2 (en) 2023-12-14
CN115667240B (zh) 2025-04-22
CN115667240A (zh) 2023-01-31
CA3180829A1 (en) 2021-11-25
TW202504893A (zh) 2025-02-01
KR20250048392A (ko) 2025-04-08
CN120168469A (zh) 2025-06-20
US20210371394A1 (en) 2021-12-02
IL297975A (en) 2023-01-01
AU2021276912A1 (en) 2022-11-24
KR20230009478A (ko) 2023-01-17
WO2021234544A1 (en) 2021-11-25
EP4153580A1 (en) 2023-03-29
US11603363B2 (en) 2023-03-14
CN120208923A (zh) 2025-06-27
US20230265067A1 (en) 2023-08-24
JP7592743B2 (ja) 2024-12-02
AU2024201640A1 (en) 2024-04-04
US12384758B2 (en) 2025-08-12
JP7789850B2 (ja) 2025-12-22
AU2024201640B2 (en) 2025-10-09
US20250270186A1 (en) 2025-08-28

Similar Documents

Publication Publication Date Title
CN115667240B (zh) Lnp023的结晶形式
US20250188054A1 (en) Crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
EP3808742A1 (en) Polymorph of selinexor
WO2020214921A1 (en) Solid forms of modulators of cftr
US12590095B2 (en) Crystalline forms of an orally available, selective kit and PDGFR kinase inhibitor
JP2018168153A (ja) 6−{2−[1−(6−メチル−3−ピリダジニル)−4−ピペリジニル]エトキシ}−3−エトキシ−1,2−ベンゾイソオキサゾールの無水結晶性遊離塩基形態
RU2818684C1 (ru) Кристаллическая форма lnp023
HK40127061A (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
WO2022263263A1 (en) Crystalline form of avacopan
HK40065390A (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
HK40065390B (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer